ArticleNucleic acids research2019
Intracellular selection of trans-cleaving hammerhead ribozymes.
Article in Nucleic acids research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- The RNA structural code: orchestrating gene expression and enabling precision therapies.Acta pharmacologica Sinica · 2026Review
- Rational design of hammerhead ribozymes as CD93 silencing tools for vascular diseases.Molecular therapy. Nucleic acids · 2026Article
- De novo-designed ribozyme-controlled riboregulator for cell-free diagnostics.Nature communications · 2026Article
- Systematic discovery of novel ribozymes with gene silencing properties from global deep-sea RNA viromes.Frontiers in microbiology · 2026Article
- Aptazyme-mediated gene regulation in Strongyloides stercoralis for functional studies of insulin receptor isoform specificity.PLoS pathogens · 2025Article
- Hammerhead Ribozymes: Structural Insights, Catalytic Mechanisms, and Cutting-Edge Applications in Synthetic Biology.International journal of molecular sciences · 2025Review
- A hammerhead ribozyme selects mechanically stable conformations for catalysis against viral RNA.Communications biology · 2025Article
- Hammerhead ribozymes directed against mRNA of an essential gene inhibitFrontiers in microbiology · 2025Article
- Article
- Article
- Riboswitches, from cognition to transformation.Synthetic and systems biotechnology · 2023Review
- The emerging roles of long noncoding RNAs in lymphatic vascular development and disease.Cellular and molecular life sciences : CMLS · 2023Review
- Specificity of oligonucleotide gene therapy (OGT) agents.Theranostics · 2022Review
- Codon-Reduced Protein Synthesis With Manipulating tRNA Components in Cell-Free System.Frontiers in bioengineering and biotechnology · 2022Review
- An in vivo selection system with tightly regulated gene expression enables directed evolution of highly efficient enzymes.Scientific reports · 2021Article
- RNAs That Behave Like Prions.mSphere · 2020Article
- Intracellular Selection of Theophylline-Sensitive Hammerhead Aptazyme.Molecular therapy. Nucleic acids · 2020Article
- Frame-shifted proteins of a given gene retain the same function.Nucleic acids research · 2020Article
- Catalytic Nucleic Acids: Biochemistry, Chemical Biology, Biosensors, and Nanotechnology.iScience · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hammerhead ribozyme is the smallest and best characterized catalytic RNA-cleaving ribozyme. It has been reported as potential therapeutic tools to manipulate the expression of target genes. However, most of naturally occurring hammerhead ribozymes process self-cleavage rather than cleave substrate RNA in trans, and its high intracellular activity relies on the tertiary interaction of Loop II and steam I bulge, resulting in decreased performance as applied in gene silencing. We described a direct intracellular selection method to evolve hammerhead variants based on trans-cleavage mode via using a toxin gene as the reporter. And a dual fluorescence proteins system has also been established to quantitatively evaluate the efficiency of selected ribozymes in the cell. Based on this selection strategy, we obtained three mutants with enhanced intracellular cleaving activity compared to wide type hammerhead ribozyme. The best one, TX-2 was revealed to possess better and consistent gene knockdown ability at different positions on diverse targeted mRNA either in prokaryotic or eukaryotic cells than wild-type hammerhead ribozyme. These observations imply the efficiency of the intracellular selection method of the trans-acting ribozyme and the potentials of improved ribozyme variants for research and therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.